Today’s Price Action: Will ChemoCentryx Inc Short Squeeze Soon?

Today's Price Action: Will ChemoCentryx Inc Short Squeeze Soon?

The stock of ChemoCentryx Inc (NASDAQ:CCXI) is a huge mover today! About 202,428 shares traded hands or 7.32% up from the average. ChemoCentryx Inc (NASDAQ:CCXI) has risen 118.18% since April 6, 2016 and is uptrending. It has outperformed by 116.23% the S&P500.
The move comes after 8 months negative chart setup for the $352.07M company. It was reported on Nov, 8 by Barchart.com. We have $6.04 PT which if reached, will make NASDAQ:CCXI worth $38.73M less.

Analysts await ChemoCentryx Inc (NASDAQ:CCXI) to report earnings on November, 14.

According to Zacks Investment Research, “ChemoCentryx, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. ChemoCentryx, Inc. is headquartered in Mountain View, California.”

Insitutional Activity: The institutional sentiment decreased to 1.11 in Q2 2016. Its down 0.65, from 1.76 in 2016Q1. The ratio is negative, as 12 funds sold all ChemoCentryx Inc shares owned while 23 reduced positions. 20 funds bought stakes while 19 increased positions. They now own 22.71 million shares or 5.49% less from 24.03 million shares in 2016Q1.
Nationwide Fund holds 0% or 96,077 shares in its portfolio. Northern Tru owns 227,673 shares or 0% of their US portfolio. Blackrock Fund Advisors holds 1.16M shares or 0% of its portfolio. Wasatch accumulated 2.57M shares or 0.18% of the stock. Boston Prns last reported 255,815 shares in the company. Alliancebernstein L P has invested 0% of its portfolio in ChemoCentryx Inc (NASDAQ:CCXI). The California-based Wells Fargo And Mn has invested 0% in ChemoCentryx Inc (NASDAQ:CCXI). Schwab Charles Inv accumulated 0% or 32,000 shares. Belmont Global Advisors owns 80,000 shares or 0.34% of their US portfolio. Tower Research Ltd (Trc) holds 753 shares or 0% of its portfolio. Deutsche Commercial Bank Ag accumulated 0% or 204,444 shares. Bnp Paribas Arbitrage reported 841 shares or 0% of all its holdings. New York State Common Retirement Fund has invested 0% of its portfolio in ChemoCentryx Inc (NASDAQ:CCXI). Citigroup reported 2,116 shares or 0% of all its holdings. Connective Cap Mgmt Ltd Limited Liability Company has 2.58% invested in the company for 191,881 shares.

Insider Transactions: Since May 13, 2016, the stock had 3 insider buys, and 3 sales for $396,091 net activity. 25,000 shares were bought by Edwards Thomas A., worth $101,213 on Monday, May 16. $24,411 worth of ChemoCentryx Inc (NASDAQ:CCXI) shares were sold by LUCAS ROGER C. Another trade for 5,544 shares valued at $24,337 was sold by Tyree James L. 40,000 shares were bought by Parker Geoffrey M., worth $161,388 on Friday, May 13.

Another recent and important ChemoCentryx Inc (NASDAQ:CCXI) news was published by Quotes.Wsj.com which published an article titled: “ChemoCentryx Inc. CCXI (US: Nasdaq)” on February 04, 2012.

CCXI Company Profile

ChemoCentryx, Inc. (ChemoCentryx), incorporated on November 8, 1996, is a biopharmaceutical company. The Firm is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment